BioSpace News Archive

Hutchison China MediTech Limited announces that its New Drug Application for surufatinib for the treatment of patients with advanced pancreatic neuroendocrine tumors has been accepted for review by the China National Medical Products Administration.

Applied Therapeutics, Inc. announced that it will present two poster presentations covering AT-001, a next generation aldose reductase inhibitor, in Phase 3 development for Diabetic Cardiomyopathy at the upcoming 56th Annual Meeting of the European Association for the Study of Diabetes.

Passage Bio, Inc. announced publication of data supporting development of its gene therapy PBFTO2 for patients with frontotemporal dementia caused by mutations in the granulin gene.

Dogma Therapeutics has reached an agreement for the acquisition of its oral PCSK9 program by AstraZeneca. Dogma will receive upfront as well as downstream payments linked to global regulatory and commercial milestones.

First user-driven analytics community to help consolidate best practices and knowledge base on medical equipment usage and diagnostics

Merz Aesthetics ® Taps Gwyneth Paltrow as the Global Face of Xeomin ® (incobotulinumtoxinA) This campaign is the first-ever medical aesthetics partnership for goop ® Founder, Gwyneth Paltrow RALEIGH, N.C.--( BUSINESS WIRE )-- Merz Aesthetics, the world’s largest dedicated medical aesthetics business, announced today a partnership with Oscar and Emmy-award-winning actor, author and entrepreneur, Gwyneth Paltrow, for the launch of the company’s firs

Dr. Reddy’s licensed to sell volume-limited amounts of generic lenalidomide in the U.S. beginning on a confidential date after the March 2022 date previously granted to Natco Dr. Reddy’s also licensed to sell generic lenalidomide in the U.S. without volume limitation beginning on January 31, 2026 The earliest licensed entry of any generic lenalidomide in the U.S. continues to be March 2022, based on settlements reached NEW YORK--( BUSIN

- Rebastinib Combined with Paclitaxel Showed Encouraging Preliminary Clinical Benefit and Favorable Tolerability in Patients with Platinum-resistant Ovarian Cancer - - Rebastinib Combined with Carboplatin was Well-tolerated in Patients with Metastatic Solid Tumors and Showed Initial Clinical Activity - WALTHAM, Mass.--( BUSINESS WIRE )-- Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), today announced the presentation of data from the ovarian

Positive interim analysis from Phase 2 study of CMV vaccine candidate (mRNA-1647); Phase 3 study to begin in 2021 Phase 3 COVE study of COVID vaccine candidate (mRNA-1273) has enrolled 25,296 participants to date; Phase 3 protocol now available online Moderna to enter seasonal flu business given the high medical need for more effective flu vaccine Two-dose regimen of Chikungunya antibody (mRNA-1944) demonstrates the platform’s ability

Preliminary pharmacokinetic and biomarker data support continued evaluation of Cami as a novel immuno-oncology approach for patients with solid tumor cancers LAUSANNE, Switzerland--( BUSINESS WIRE )-- ADC Therapeutics SA (NYSE: ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent and targeted antibody drug conjugates (ADCs) for patients with hematological malignancies